Biocon Launches Bosaya & Aukelso in US, Targeting $5B Market

Biocon Enters U.S. Bone Health Market with Biosimilar Launch

Biocon Limited, a global biopharmaceutical company based in India, announced the commercial launch of two key biosimilars, Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq), in the United States. These products are now available by prescription nationwide, marking a significant expansion of Biocon's portfolio into the lucrative U.S. bone health market. The launch aims to provide more affordable treatment options for patients with osteoporosis and cancer-related bone complications.

Bosaya™ is a biosimilar to Amgen's Prolia®, while Aukelso™ is a biosimilar to Amgen's Xgeva®. Both received U.S. Food and Drug Administration (FDA) approval in September 2025, along with an interchangeable designation. This status allows pharmacists to substitute the biosimilar for the reference product, in accordance with state laws, potentially accelerating adoption and increasing patient access.

Strategic Importance for Biocon

Shreehas Tambe, CEO and Managing Director of Biocon Limited, highlighted the strategic nature of this launch. "The U.S. introduction of Bosaya™ and Aukelso™ marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology," he stated. Tambe emphasized that these therapies will broaden access to high-quality, affordable treatments for patients with serious bone conditions. He added, "This milestone underscores Biocon’s strength as a portfolio development engine and our focus on building the world’s most scalable access platform."

The move positions Biocon to compete in a substantial market. In 2024, sales of denosumab products in the United States reached approximately $1 billion, indicating strong demand. The availability of lower-cost biosimilars is expected to benefit the estimated 10 million adults with osteoporosis and over 330,000 patients diagnosed annually with bone metastasis from advanced cancer.

The Path to Commercialization

The commercial launch follows a critical settlement agreement reached between Biocon's subsidiary, Biocon Biologics, and Amgen Inc. in October 2025. This agreement resolved pending patent litigation and cleared the legal pathway for Biocon to introduce its denosumab biosimilars to the U.S. market. The settlement was a key step that followed the FDA's approval and interchangeability designation a month earlier, demonstrating a well-executed market entry strategy.

Product and Treatment Details

Denosumab is a human monoclonal antibody that plays a vital role in bone health. It functions by targeting and binding to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a protein essential for the formation and survival of osteoclasts—the cells responsible for breaking down bone tissue. By inhibiting RANKL, denosumab effectively reduces bone resorption, leading to increased bone mass and strength.

Biocon is offering both products in the most common presentations to ensure they meet the needs of healthcare providers and patients.

Safety and Patient Considerations

As with the reference products, Bosaya™ carries a warning for severe hypocalcemia (low calcium levels in the blood), particularly in patients with advanced chronic kidney disease (CKD). The FDA has approved Bosaya™ with the same Risk Evaluation and Mitigation Strategy (REMS) as Prolia® to ensure healthcare providers are aware of this risk and can manage patients appropriately. Treatment for patients with advanced CKD should be supervised by a healthcare provider with expertise in managing CKD-Mineral and Bone Disorder (CKD-MBD).

Market Impact and Future Outlook

The introduction of Bosaya™ and Aukelso™ is expected to increase competition in the U.S. biologics market, potentially leading to price reductions and wider accessibility for denosumab treatments. For Biocon, this launch strengthens its presence in the advanced markets of the U.S. and Europe and diversifies its therapeutic footprint beyond its core areas of diabetes and autoimmune diseases. It reinforces the company's position as a key player in the global biosimilars industry, committed to providing affordable alternatives to complex biologic medicines.

This move aligns with Biocon's long-term strategy of developing and commercializing a broad portfolio of biosimilars and generics to address critical healthcare needs worldwide. The successful entry into the U.S. bone health segment paves the way for future growth and further establishes the company's reputation for quality and affordability.